The present invention relates to peptides, nucleic acids, binding agents, methods and cells for use in immunotherapy. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated cytotoxic T lymphocyte (CTL) peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumour immune responses. The present invention relates to a peptide sequence derived from HLA class 1 molecules of human tumour cells that can be used for eliciting anti-tumour immune responses.
